1 Patient Report

Specimen ID: 104-988-9013-0 Acct #: 90000999 Phone: (336) 436-8645 Rte: 00

Control ID: LabCorp Test Master
Test Account
SAMPLE REPORT 1, 139900 5450 Millstream Road
MCLEANSVILLE NC 27301



















Patient Details Specimen Details Physician Details

DOB: 03/15/1959 Date collected: 04/14/2021 0000 Local Ordering:
Age(y/m/d): 062/00/30 Date received: 04/14/2021 Referring:
Gender: M Date entered: 04/14/2021 ID:
Patient ID: Date reported: 04/14/2021 0855 ET NPI:
General Comments & Additional Information
Clinical Info: NOT DETECTED
Ordered Items
SARS-CoV-2, NAA
TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB
SARS-CoV-2, NAA
SARS-CoV-2, NAA Not Detected Not Detected 01
This nucleic acid amplification test was developed and its performance
characteristics determined by LabCorp Laboratories. Nucleic acid
amplification tests include RT-PCR and TMA. This test has not been
FDA cleared or approved. This test has been authorized by FDA under
an Emergency Use Authorization (EUA). This test is only authorized
for the duration of time the declaration that circumstances exist
justifying the authorization of the emergency use of in vitro
diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis
of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C.
360bbb-3(b) (1), unless the authorization is terminated or revoked
sooner.
When diagnostic testing is negative, the possibility of a false
negative result should be considered in the context of a patient's
recent exposures and the presence of clinical signs and symptoms
consistent with COVID-19. An individual without symptoms of COVID-19
and who is not shedding SARS-CoV-2 virus would expect to have a
negative (not detected) result in this assay.
SARS-CoV-2, NAA 2 DAY TAT
Performed 02

01 BN LabCorp Burlington Dir: Sanjai Nagendra, MD

1447 York Court, Burlington, NC 27215-3361
02 $$ Testmaster Testing Dir: Report Testing, PhD
3060 S Church Street, Burlington, NC 27215
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762

Date Issued: 04/14/21 0857 ET FINAL REPORT Page 1 of 1

This document contains private and confidential health information protected by state and federal law.
1995-2021 Laboratory Corporation of America
Holdings
If you have received this document in error, please call 800-222-7566 1.00
All Rights Reserved - Enterprise Report Version: 
1 Patient Report



Specimen ID: 104-988-9014-0 Acct #: 90000999 Phone: (336) 436-8645 Rte: 00
Control ID: LabCorp Test Master
Test Account
SAMPLE REPORT 2, 139900 5450 Millstream Road
MCLEANSVILLE NC 27301



















Patient Details Specimen Details Physician Details

DOB: 02/02/1982 Date collected: 04/14/2021 0000 Local Ordering:
Age(y/m/d): 039/02/12 Date received: 04/14/2021 Referring:
Gender: M Date entered: 04/14/2021 ID:
Patient ID: Date reported: 04/14/2021 1443 ET NPI:
General Comments & Additional Information
Clinical Info: DETECTED
Ordered Items
SARS-CoV-2, NAA
TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB
SARS-CoV-2, NAA
SARS-CoV-2, NAA Detected Abnormal Not Detected 01
Patients who have a positive COVID-19 test result may now have
treatment options. Treatment options are available for patients
with mild to moderate symptoms and for hospitalized patients.
Visit our website at https://www.labcorp.com/COVID19 for
resources and information.
This nucleic acid amplification test was developed and its performance
characteristics determined by LabCorp Laboratories. Nucleic acid
amplification tests include RT-PCR and TMA. This test has not been
FDA cleared or approved. This test has been authorized by FDA under
an Emergency Use Authorization (EUA). This test is only authorized
for the duration of time the declaration that circumstances exist
justifying the authorization of the emergency use of in vitro
diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis
of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C.
360bbb-3(b) (1), unless the authorization is terminated or revoked
sooner.
When diagnostic testing is negative, the possibility of a false
negative result should be considered in the context of a patient's
recent exposures and the presence of clinical signs and symptoms
consistent with COVID-19. An individual without symptoms of COVID-19
and who is not shedding SARS-CoV-2 virus would expect to have a
negative (not detected) result in this assay.
SARS-CoV-2, NAA 2 DAY TAT
Performed 02

01 BN LabCorp Burlington Dir: Sanjai Nagendra, MD

1447 York Court, Burlington, NC 27215-3361
02 $$ Testmaster Testing Dir: Report Testing, PhD
3060 S Church Street, Burlington, NC 27215
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762

Date Issued: 04/14/21 1444 ET FINAL REPORT Page 1 of 1

This document contains private and confidential health information protected by state and federal law.
1995-2021 Laboratory Corporation of America
Holdings
If you have received this document in error, please call 800-222-7566 1.00
All Rights Reserved - Enterprise Report Version: 
1 Patient Report



Specimen ID: 104-988-9015-0 Acct #: 90000999 Phone: (336) 436-8645 Rte: 00
Control ID: LabCorp Test Master
Test Account
SAMPLE REPORT 3, 139900 5450 Millstream Road
MCLEANSVILLE NC 27301



















Patient Details Specimen Details Physician Details

DOB: 07/04/1976 Date collected: 04/14/2021 0000 Local Ordering:
Age(y/m/d): 044/09/10 Date received: 04/14/2021 Referring:
Gender: M Date entered: 04/14/2021 ID:
Patient ID: Date reported: 04/14/2021 0855 ET NPI:
General Comments & Additional Information
Clinical Info: INDETERMINATE
Ordered Items
SARS-CoV-2, NAA
TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB
SARS-CoV-2, NAA
SARS-CoV-2, NAA Indeterminate Abnormal Not Detected 01
We are UNABLE to reliably determine a result for the specimen due to
the inconsistent amplification of all of the required SARS-CoV-2
components from the specimen submitted. If clinically indicated,
please recollect an additional specimen for testing.
This nucleic acid amplification test was developed and its performance
characteristics determined by LabCorp Laboratories. Nucleic acid
amplification tests include RT-PCR and TMA. This test has not been
FDA cleared or approved. This test has been authorized by FDA under
an Emergency Use Authorization (EUA). This test is only authorized
for the duration of time the declaration that circumstances exist
justifying the authorization of the emergency use of in vitro
diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis
of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C.
360bbb-3(b) (1), unless the authorization is terminated or revoked
sooner.
When diagnostic testing is negative, the possibility of a false
negative result should be considered in the context of a patient's
recent exposures and the presence of clinical signs and symptoms
consistent with COVID-19. An individual without symptoms of COVID-19
and who is not shedding SARS-CoV-2 virus would expect to have a
negative (not detected) result in this assay.
SARS-CoV-2, NAA 2 DAY TAT
Performed 02

01 BN LabCorp Burlington Dir: Sanjai Nagendra, MD

1447 York Court, Burlington, NC 27215-3361
02 $$ Testmaster Testing Dir: Report Testing, PhD
3060 S Church Street, Burlington, NC 27215
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762

Date Issued: 04/14/21 0859 ET FINAL REPORT Page 1 of 1

This document contains private and confidential health information protected by state and federal law.
1995-2021 Laboratory Corporation of America
Holdings
If you have received this document in error, please call 800-222-7566 1.00
All Rights Reserved - Enterprise Report Version: